We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Vicore Pharma Holding AB (VICO) NPV

Sell:7.74 SEK Buy:7.78 SEK Change: 0.01 SEK (0.13%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:7.74 SEK
Buy:7.78 SEK
Change: 0.01 SEK (0.13%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
Sell:7.74 SEK
Buy:7.78 SEK
Change: 0.01 SEK (0.13%)
Market closed |  Prices as at close on 21 November 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.

Contact details

Address:
Kornhamnstorg 53
STOCKHOLM
111 27
Sweden
Telephone:
+46 (31) 7880560
Website:
https://vicorepharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VICO
ISIN:
SE0007577895
Market cap:
1.83 billion SEK
Shares in issue:
111.73 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Hans Schikan
    Independent Chairman of the Board
  • Ahmed Mousa
    Chief Executive Officer
  • Hans Jeppsson
    Chief Financial Officer
  • Nina Carlen
    Chief Administrative Officer
  • Johan Raud
    Chief Scientific Officer
  • Mikael Nygard
    Vice President - Operations and Corporate Strategy
  • Elin Rosendahl
    Vice President - Clinical Development
  • Jimmie Hofman
    Vice President - Business Development
  • Sophie Bertilsson
    Interim Head of CMC
  • Johanna Graens
    Program Director - Early Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.